Medicxi Ventures

Investor type Venture Capital
Founders David Grainger Francesco Rubertis Giuseppe Zocco Kevin Johnson Michele Ollier


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 36
Average round size
The average size of a deal this fund participated in
Portfolio companies 29
Rounds per year 7.20
Lead investments 18
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 4
Key employees 11

Areas of investment

  • Biotechnology
  • Pharmaceutical
  • Therapeutics
  • Health Care
  • Medical

In 2016 was created Medicxi Ventures, which is appeared as VC. The fund was located in Europe if to be more exact in United Kingdom. The leading representative office of defined VC is situated in the London.

Among the various public portfolio startups of the fund, we may underline SutroVax, Diasome, Aura Biosciences Among the most successful fund investment fields, there are Biopharma, Genetics. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. The fund has specific favorite in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low.

The fund was created by David Grainger, Francesco Rubertis, Giuseppe Zocco, Kevin Johnson, Michele Ollier. The overall number of key employees were 11.

The usual things for fund are deals in the range of 10 - 50 millions dollars. Speaking about the real fund results, this VC is 54 percentage points more often commits exit comparing to other organizations. The higher amount of exits for fund were in 2018. The fund is constantly included in 2-6 investment rounds annually. The high activity for fund was in 2017. Despite it in 2019 the fund had an activity. Opposing the other organizations, this Medicxi Ventures works on 20 percentage points less the average amount of lead investments.

The typical case for the fund is to invest in rounds with 2-3 participants. Despite the Medicxi Ventures, startups are often financed by Ysios Capital, Roche Venture Fund, Longitude Capital. The meaningful sponsors for the fund in investment in the same round are RA Capital Management, University of Cambridge Enterprise, OUP (Osage University Partners). In the next rounds fund is usually obtained by Silicon Valley Bank, Oberland Capital, Kite Pharma.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Medicxi Ventures:
Typical Co-investors
Medicxi Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Medicxi Ventures:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Angel Healthcare Investors Massachusetts, Newton, United States
Ascendas-Singbridge Central, Central Region, Singapore
Baylis Medical Company Canada, Montréal, Quebec
BioCrossroads Indiana, Indianapolis, United States
Candela Partners California, San Francisco, United States
Exium Partners Fairport, New York, United States
Just Business California, San Francisco, United States
Liberty Technologies, Inc. Liberty, Missouri, United States
Meiwei Buyongdeng China, Shanghai
New Era Ventures District of Columbia, United States, Washington
Nifco England, Stockton-on-Tees, United Kingdom
Pacific West Bank Oregon, United States, West Linn
Palm Beach Capital Florida, United States, West Palm Beach
PaRan GongCheng Beijing, Beijing, China
Shilan Zichan Guanli -
Sigma Capital Group City of Edinburgh, Scotland, United Kingdom
Stratel Norway, Oslo
Velvet Sea Ventures Delaware, Dover, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


Life Science
$47M08 Sep 2021 Nijmegen, Gelderland, Netherlands

Versanis Bio

Life Science
$70M31 Aug 2021 Oakland, California, United States


$45M10 Aug 2021 California, United States

Rivus Pharmaceuticals

Health Care
$35M20 Jul 2021 Charlottesville, Virginia, United States

Kurome Therapeutics

Health Care
$15M10 Jun 2021 Cincinnati, Ohio, United States

Aura Biosciences

Health Care
$80M22 Mar 2021 Cambridge, Massachusetts, United States


App Discovery
$10M07 Oct 2020 Cambridge, Massachusetts, United States

Palladio Biosciences

$20M25 Sep 2020 Horsham Township, Pennsylvania, United States

Checkmate Pharmaceuticals

Medical Device
$85M10 Jun 2020 Cambridge, Massachusetts, United States
Versanis Bio Raises $70M in Series A Financing

– Versanis Bio is an Oakland, Calif.-based company established to discover and develop first-in-class medicines that address medical conditions prevalent in older adults.
– The company closed a $70m Series A financing.
– The round was co-led by Atlas Venture and Medicxi with participation from Aditum Bio.
– The company intends to use the funds to advance a comprehensive phase 2 clinical program to evaluate the potential of bimagrumab to help obese patients lose fat and achieve an improved body composition.

Sydnexis Secures $45 Million Series B Financing Led by Visionary Ventures and Blue Stem Capital

– Sydnexis, Inc. completed a $45m Series B financing led by Visionary Ventures, Blue Stem Capital, and SC Master Fund, with participation from existing investors RA Capital Management, Longitude Capital, and Medicxi.
– The financing will be used to fund Sydnexis’ lead candidate, SYD-101, through completion of the fully enrolled pivotal Phase 3 STAAR study for the treatment of progressive myopia in children.
– Sydnexis’ STAAR study is the largest pediatric myopia study globally to investigate the use of low dose atropine to retard progressive myopia. In this study, Sydnexis is evaluating two different concentrations of its proprietary atropine formulation SYD-101 (0.01% and 0.03%) versus a placebo control group.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Medicxi Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: